ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | US

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
NLS Pharmaceutics Ltd. Developing therapies for rare CNS disorders, specializing in narcolepsy and sleep-wake issues.	United States of America	NLSP
NovaBay Pharmaceuticals, Inc. Develops clinically-proven anti-infective therapies for eyecare, skincare, and wound care.	United States of America	NBY
Novacyt Designs and supplies molecular diagnostic tests and PCR kits for human, veterinary, and food safety.	France	ALNOV
Novartis AG Develops and markets innovative medicines globally using advanced science and technology.	Switzerland	NOVN
NOVARTIS AG Researches, develops, and markets patented and generic pharmaceuticals for patients globally.	United States of America	NVS
NOVAVAX INC Develops and commercializes nanoparticle vaccines for serious infectious diseases.	United States of America	NVAX
NovMetaPharma Co., Ltd. Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.	South Korea	229500
Novo Nordisk Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.	Denmark	NOVO
NOVO NORDISK A S Develops innovative medicines for diabetes, obesity, and rare blood & endocrine disorders.	United States of America	NVO
NRX Pharmaceuticals, Inc. Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.	United States of America	NRXP